Key points from article :
Iambic Therapeutics has unveiled Enchant, a new AI model designed to bridge the gap between lab research and clinical drug development. The San Diego-based biotech, which has already used AI to bring its first drug candidate into clinical trials, believes Enchant marks a significant leap forward in AI-driven drug discovery. Unlike traditional methods, the model leverages a vast dataset of preclinical and research data, with a small portion of clinical data, to predict how experimental drugs will behave in the human body.
In its early testing, Enchant outperformed existing models in predicting key drug properties, such as half-life—how long a drug remains active in the body. It achieved a correlation score of 0.73, surpassing the previous best of 0.58. This advancement, according to Iambic’s leadership, signals a major breakthrough in using AI to improve clinical success rates. Unlike competitors such as Google DeepMind’s Tx-LLM and Insilico’s nach0, Enchant focuses on clinical predictions rather than just protein structure modelling, positioning it as a game-changer in AI-driven biotechnology.
Despite promising results, Enchant’s findings have not yet been peer-reviewed, though Iambic expects to publish more detailed studies in the future. The company remains confident that Enchant can outperform current models across multiple clinical predictions, potentially revolutionizing how new drugs are developed and tested.
